Sahajanand Medical Technologies IPO Details
MAINBOARD
Sahajanand Medical Technologies IPO DRHP (Draft Red Herring Prospectus) has been SEBI Approval Received.
Sahajanand Medical Technologies IPO total issue size comprises 2,76,44,231 shares . Pre-issue shareholding stands at 10,14,03,232, which will increase to 10,14,03,232 post-issue.
The Lead Managers for Sahajanand Medical Technologies IPO are crucial for the offering's success. They are responsible for a wide range of tasks, including preparing the company for the public market, managing the regulatory filings, and marketing the IPO to potential investors. The lead manager for this offering is Nuvama Wealth Management Ltd, HSBC Securities & Capital Markets Pvt Ltd, Motilal Oswal Investment Advisors Ltd, Avendus Capital Pvt Ltd. To assess their past performance and success in previous IPOs, you can view the Lead Manager Performance Summary report.
For detailed information, Refer to the Sahajanand Medical Technologies Limited DRHP.
Sahajanand Medical Technologies IPO Details
Sahajanand Medical Technologies IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
To be announced | |||
Sahajanand Medical Technologies IPO Reservation
Promoter Holding
Documents
Sahajanand Medical Technologies IPO Valuations
Sahajanand Medical Technologies Financial Information
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
| Assets | 1,094.90 | 970.58 | 911.63 |
| Total Income | 1,035.96 | 908.59 | 803.28 |
| Profit After Tax | 25.15 | -7.35 | 11.93 |
| EBITDA | 110.77 | 110.05 | 110.77 |
| Net Worth | 545.23 | 526.30 | 539.21 |
| Reserves and Surplus | 580.71 | 556.57 | 563.35 |
| Total Borrowing | 224.96 | 175.27 | 132.18 |
| Amount in ₹ Crore | |||
About Sahajanand Medical Technologies IPO
Founded in 2001 by Mr. Dhirajlal Kotadia, Sahajanand Medical Technologies Ltd. is a medical device company focused on Class III and Class C/D devices, primarily in the fields of vascular and structural heart intervention. The company was the first globally to receive CE certification for a drug-eluting stent (DES) with a biodegradable polymer—Infinnium.
The product portfolio spans three key categories:
- Vascular Intervention (VI): Includes coronary stents and balloons for minimally invasive blood vessel treatments.
- Structural Heart (SH): Covers advanced technologies such as Transcatheter Aortic Valve Implantation (TAVI) and Occluders.
- Other Products: Includes renal stents, peripheral Drug-Coated Balloons (DCBs), and selected trading products.
Sahajanand operates two R&D centers—one in India and one in Thailand—supported by a team of 102 professionals, including biomedical engineers and clinical research specialists. The company has built a robust intellectual property base, with 102 patents granted globally and 71 pending patent applications, along with five design registrations in India.
Key products such as Supraflex Cruz (DES), Hydra (TAVI), and Cocoon (Occluders) are backed by 72 clinical studies, and are widely accepted in over 76 countries across Europe, Asia, and other regions. The global distribution strategy includes direct operations in key European markets (Germany, Spain, France, UK), hybrid models in India (serving hospitals like Narayana Hrudayalaya Limited), and distributor-led entry in markets such as Italy.
International market adoption is reinforced by endorsements from key opinion leaders (KOLs), successful government tenders, and partnerships with major Group Purchasing Organizations (GPOs) in Europe.
The company follows a “House of Brand” strategy, developing and commercializing clinically differentiated products under recognized brand names like Supraflex Cruz, Hydra, and Cocoon.
As of March 31, 2025, Sahajanand Medical Technologies employed 1,458 full-time staff, 24 consultants, and 818 contract-based personnel across its operations.
Strength Of Sahajanand Medical Technologies IPO
Risk Of Sahajanand Medical Technologies IPO
Objectives Sahajanand Medical Technologies IPO
1. The company will not receive any proceeds from the Offer.
Company Contact Details
Sahajanand Medical Technologies Ltd.
Sahajanand Estate, Wakharia Wadi,
NR. Dabholi Char Rasta
Nani Ved, Ved Road
Surat, Gujarat, 395004
Phone: 022 49564000
Email: investors.grievance@smt.in
Website: http://www.smtpl.com/
Registrar Contact Details
Sahajanand Medical Technologies IPO - FAQs
The Sahajanand Medical Technologies IPO is a MAINBOARD public issue comprising 27644231 equity shares with a face value of ₹1 each, aggregating to a total issue size of . The issue price has been fixed at ₹0 per equity share, and the minimum application size is 0 shares.
The IPO opens for subscription on TBA, and closes on TBA.
MUFG Intime India Pvt Ltd has been appointed as the registrar to the issue. The equity shares are proposed to be listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE).
As of now, the current GMP stands at TBA.